Advances in the mechanisms of molecular chaperones and the development of Hsp90 inhibitors may be conducive to stimulate a new generation of therapies that are critical not only for cancer but also for other protein misfolding diseases such as neurodegenerative diseases. The gene discussed is HSP90AA1; the disease is cancer.